#ACC24 Late-Breaker RCT confirms Impella CP® improves survival by 12.7%, compared to the control arm without Impella, in heart attack with shock. Congratulations to Jacob Møller, MD, and all the independent investigators on today's publication in NEJM. https://lnkd.in/edpiM3yR
Exactly as expected 👍👍!
And it’s just the small one.
This appears be be a study of Impella versus "standard" (pharma only?) support. As other forms of mechanical circulatory support (ECMO, IABP, etc) were excluded, questions regarding the statistical superiority of Impella CP still can occur.
It is a monumental task and a 10-year journey on a treacherous path lined with failed RCTs considering the severity of patient presentation. And here we have a clear winner on the outcome. Kudos to everyone involved in this trial. This is something you should be extremely proud of.
So exciting to watch Dr. Jacob Møller present these results live at #ACC24. I’m so proud to represent this clinically proven life saving therapy! #IamAbiomed #IamHeartRecovery #Patientsfirst
Finally, some hard evidence on the subject. Validates what Impella users around the world already believed - MCS with Impella can be a viable tool for patients in cardiogenic shock. 👏🏻 🍾 🥳 Well done.